Otsuka Pharmaceutical yanked its European application for broader use of Abilify; it had asked the EMEA for permission to market the antipsychotic drug as a treatment for depression. Report [1]
Links:
[1] http://www.pharmatimes.com/WorldNews/article.aspx?id=16944